Developer docs
API playgroundTry for free, no card

Search company profiles

eQcell

Full company profile

uuid0004d4j

Namestring
eQcell
Legal namestring
eQcell Inc.
Websiteurl
eqcell.com
Company typeenum
Private
Founded yearint
2010
Descriptiontext

eQcell Inc. is a Canadian clinical-stage regenerative medicine company founded in 2010 and headquartered at the University of Guelph's Ontario Veterinary College (OVC) campus in Guelph, Ontario. The company develops allogeneic mesenchymal stromal cell (MSC) therapies for veterinary applications, specifically equine cord blood-derived MSCs (CB-MSCs) for horses and canine adipose-derived MSCs for dogs, targeting musculoskeletal conditions including osteoarthritis, synovitis, septic arthritis, tendinopathies, and tendon/ligament injuries for which current treatments are palliative or ineffective. eQcell's proprietary MSC activation methods and bioreactor-based cell expansion protocols are designed to enhance therapeutic capacity and produce clinically relevant cell quantities at scale.

The company's commercial vehicle is the eQcell Quality Cell Series™, which currently includes banked allogeneic cells designated for research use and autologous MSC isolation services offered to Canadian veterinarians. Its primary go-to-market motion is conducted through clinical trials with academic veterinary institutions including OVC, Colorado State University, and UC Davis Veterinary Medicine. The company operates an open INAD with the FDA for GMP manufacturing platform concurrence and within Health Canada's Veterinary Drug Directorate Experimental Studies Certificate (ESC) framework. Allogeneic cell use in client-owned animals currently requires an approved ESC; autologous services do not.

eQcell is pre-commercial. Revenue today is limited to MSC isolation services and research-only cell sales in Canada, with one-time license economics expected once veterinary approvals are achieved. The company has completed capital raises in December 2021 (undisclosed) and August 2022 (Ag Capital Canada, disclosed investment in source funding table) and is actively soliciting additional investors. Over $6,000,000 in cumulative grant funding has been secured from sources including Equine Guelph, NSERC, CIHR, Morris Animal Foundation, and Grayson Jockey Club Research Foundation. Pivotal trials designed to support marketing approvals are anticipated to initiate in 2026.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersGuelph, Canada
HQ citystring
Guelph
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
veterinary regenerative medicine, allogeneic stem cell therapy, mesenchymal stromal cells, equine cell therapy, canine osteoarthritis treatment
Industry2 codes
PRIMARYHLAMANAI
Veterinary Regenerative Medicine Manufacturing (GMP/CDMO, Cell Processing)
Healthcare & Life Sciences/Veterinary & Animal Health/Regenerative Medicine for Animals
SECONDARYHLAMANAL
Clinical Research, Trials & Translational Services (Veterinary Regenerative)
Healthcare & Life Sciences/Veterinary & Animal Health/Regenerative Medicine for Animals
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Veterinary Regenerative Medicine
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Veterinary Stem Cell Products
TypeOne Time License
Description

Once clinical trials complete and regulatory approvals achieved, eQcell will commercialize allogeneic MSC products for veterinary use in horses and dogs

eqcell.com
2MSC Isolation Services
TypeProfessional Services
Description

eQcell currently offers MSC isolation services for Canadian veterinarians for autologous use of cells in horses and dogs, and individual autologous cell banking of equine cord blood MSCs

eqcell.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Research cell products and services
ModelOtherBilling cadencePay-as-you-go
Notes

Pricing available via product and price list PDF. Cells currently designated for research use only.

eqcell.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1eQcell Quality Cell Series™
Description

Banked allogeneic cells and autologous cell services for domestic animal cells including equine and canine applications.

eqcell.com
Core offering1 text field

eQcell develops and supplies allogeneic mesenchymal stromal cell (MSC) products — equine cord blood-derived CB-MSCs and canine adipose-derived MSCs — for veterinary use, alongside MSC isolation services and autologous cell banking for Canadian veterinarians. The company is currently clinical-stage, advancing these biologics through veterinary clinical trials (with pivotal trials anticipated in 2026) toward regulatory approval via FDA INAD and Health Canada's Veterinary Drug Directorate.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Horses treated with eQcell's stem cells are 3.4x more likely to return to previous work compared with hyaluronic acid
+2 more records
Product overview1 text field

eQcell is a clinical-stage regenerative medicine company offering the eQcell Quality Cell Series™ product line, which includes banked allogeneic cells and autologous cell services. The core products consist of equine allogeneic cord blood stem cells (CB-MSCs) for treating osteoarthritis in horses and canine adipose-derived mesenchymal stromal cells for treating elbow dysplasia and osteoarthritis in dogs. The company also provides MSC isolation services and autologous cell banking for Canadian veterinarians. The company is pursuing veterinary drug approvals through clinical trials designed to generate data for pivotal trials anticipated to initiate in 2026.

Product and service5 records
1eQcell Quality Cell Series™
CategoryStem cell product line
Description

Branded product line comprising banked allogeneic cells and autologous cell services for domestic animal (equine and canine) applications, with custom cell procurement available on request.

2Equine Allogeneic Cord Blood Stem Cells (CB-MSCs)
CategoryEquine cell therapy
Description

Allogeneic equine cord blood mesenchymal stromal cells designed to provide veterinarians with off-the-shelf therapeutics for treating osteoarthritis and joint conditions in horses, replacing laborious autologous extraction-expansion-re-injection workflows.

3Canine Adipose-Derived Mesenchymal Stromal Cells
CategoryCanine cell therapy
Description

Canine adipose-derived mesenchymal stromal cells developed as an allogeneic treatment option for immune and inflammatory disorders in dogs, particularly elbow dysplasia and osteoarthritis.

4MSC Isolation Services
CategoryVeterinary laboratory service
Description

MSC isolation services provided to Canadian veterinarians for autologous use of cells in horses and dogs.

5Equine Cord Blood MSC Autologous Cell Banking
CategoryVeterinary cryopreservation service
Description

Individual autologous cell banking service for equine cord blood mesenchymal stromal cells, provided to Canadian veterinarians.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierSupportingTypeTechnology or IntegrationAnnounced on2022-02-17
Description

Licensing option agreement for proprietary hydrogels for MSC encapsulation, announced February 17, 2022.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Founding academic partner. eQcell was founded based on 15 years of scientific investigation at OVC, ranked 6th in the world for veterinary science. OVC researchers (Dr. Judith Koenig, Dr. Melissa MacIver) serve as lead investigators for clinical trials.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Dr. C. Wayne McIlwraith (Founding Director of Orthopaedic Research Center) serves on Board of Directors. Dr. Laurie Goodrich and Dr. Lynn Pezzanite serve on Scientific Advisory Board. CSU's Translational Medicine Institute is key research partner.

4Moore Equine Veterinary Services
Strategic tierSupportingTypeImplementation/ SI/ Consulting Partner
Description

Collaborating equine veterinary clinic participating in clinical trials and research activities.

eqcell.com
Strategic tierSupportingTypeImplementation/ SI/ Consulting Partner
Description

Collaborating equine veterinary hospital in Kentucky participating in research partnership for septic arthritis treatment studies.

Strategic tierSupportingTypeTechnology or Integration
Description

Technology partner providing equine performance and health analytics integration.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Sponsor for synovitis clinical trial comparing MSC treatment to hyaluronic acid.

Recent move1 record

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Regeneus is an Australian clinical-stage regenerative medicine company developing allogeneic stem cell therapies, including Progenza for osteoarthritis. It is comparable to eQcell in technology platform (allogeneic MSCs), indication focus (osteoarthritis), and clinical-stage status.

TypeBroad incumbent
Description

Vetoquinol is a global animal health pharmaceutical company with strong equine and companion-animal presence. It is comparable as a broad incumbent that markets joint and orthopedic therapeutics directly competitive with eQcell's intended indications.

TypeBroad incumbent
Description

Dechra is a global specialty animal health pharmaceuticals company that is already an eQcell clinical trial sponsor (synovitis study comparing MSC therapy to hyaluronic acid). It is a broad incumbent with deep equine veterinary relationships and represents both a near-term partner and a potential strategic acquirer of eQcell's regenerative medicine platform.

TypeBroad incumbent
Description

Elanco is a major global animal health company with a broad companion-animal and livestock portfolio. It represents a broad incumbent that has been expanding into specialty and regenerative categories and could either compete with or acquire a clinical-stage MSC asset like eQcell.

5Boehringer Ingelheim Animal Health
TypeBroad incumbent
Description

Boehringer Ingelheim Animal Health is one of the largest global animal health players, with significant equine and companion-animal pharmaceutical portfolios. It is comparable as a broad incumbent that could in-license or develop competing regenerative therapies and has the distribution muscle to dominate the equine OA market.

TypeDirect peer
Description

MediVet Biologics develops and commercializes regenerative medicine therapies for horses and companion animals, including platelet-rich plasma and stem cell products. It overlaps directly with eQcell's target indications (equine and canine joint disease) and competes for the same veterinary clinic customers.

7VetStem Biopharma
TypeDirect peer
Description

VetStem Biopharma is a U.S.-based veterinary regenerative medicine company offering autologous stem cell services for horses, dogs and cats. It is the most direct competitor to eQcell in equine and companion-animal stem cell therapy, although it relies on autologous rather than allogeneic cells.

TypeEmerging player
Description

EquiCord provides equine umbilical cord blood banking services. It is comparable to eQcell because it sits on the same equine cord blood sourcing infrastructure that underpins eQcell's allogeneic CB-MSC product, and it represents both a potential supplier and a competing entry point for equine regenerative medicine.

TypeBroad incumbent
Description

Virbac is a global animal health company with equine and companion-animal pharmaceutical offerings, including orthopedic and pain management products that compete with the indications eQcell is targeting. As a broad incumbent it is both a potential competitor and a strategic partner candidate.

TypeBroad incumbent
Description

Zoetis is the world's largest animal health company with a broad portfolio of pharmaceuticals, vaccines, diagnostics and increasingly regenerative medicine. It competes indirectly through its scale, sales force, and capital capacity and is a potential strategic partner or acquirer for eQcell's MSC platform.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights8 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

eQcell

Veterinary Regenerative Medicineeqcell.com

What eQcell does

eQcell Inc. is a Canadian clinical-stage regenerative medicine company founded in 2010 and headquartered at the University of Guelph's Ontario Veterinary College (OVC) campus in Guelph, Ontario. The company develops allogeneic mesenchymal stromal cell (MSC) therapies for veterinary applications, specifically equine cord blood-derived MSCs (CB-MSCs) for horses and canine adipose-derived MSCs for dogs, targeting musculoskeletal conditions including osteoarthritis, synovitis, septic arthritis, tendinopathies, and tendon/ligament injuries for which current treatments are palliative or ineffective. eQcell's proprietary MSC activation methods and bioreactor-based cell expansion protocols are designed to enhance therapeutic capacity and produce clinically relevant cell quantities at scale.

The company's commercial vehicle is the eQcell Quality Cell Series™, which currently includes banked allogeneic cells designated for research use and autologous MSC isolation services offered to Canadian veterinarians. Its primary go-to-market motion is conducted through clinical trials with academic veterinary institutions including OVC, Colorado State University, and UC Davis Veterinary Medicine. The company operates an open INAD with the FDA for GMP manufacturing platform concurrence and within Health Canada's Veterinary Drug Directorate Experimental Studies Certificate (ESC) framework. Allogeneic cell use in client-owned animals currently requires an approved ESC; autologous services do not.

eQcell is pre-commercial. Revenue today is limited to MSC isolation services and research-only cell sales in Canada, with one-time license economics expected once veterinary approvals are achieved. The company has completed capital raises in December 2021 (undisclosed) and August 2022 (Ag Capital Canada, disclosed investment in source funding table) and is actively soliciting additional investors. Over $6,000,000 in cumulative grant funding has been secured from sources including Equine Guelph, NSERC, CIHR, Morris Animal Foundation, and Grayson Jockey Club Research Foundation. Pivotal trials designed to support marketing approvals are anticipated to initiate in 2026.

eQcell firmographics

Firmographics
Name
eQcell
Legal name
eQcell Inc.
Website
https://eqcell.com
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

eQcell industry classification

Industry
Product category
Veterinary Regenerative Medicine
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAMANAI
Veterinary Regenerative Medicine Manufacturing (GMP/CDMO, Cell Processing)
Healthcare & Life Sciences/Veterinary & Animal Health/Regenerative Medicine for Animals
SECONDARYHLAMANAL
Clinical Research, Trials & Translational Services (Veterinary Regenerative)
Healthcare & Life Sciences/Veterinary & Animal Health/Regenerative Medicine for Animals

Keywords

  • Veterinary regenerative medicine
  • Allogeneic stem cell therapy
  • Mesenchymal stromal cells
  • Equine cell therapy
  • Canine osteoarthritis treatment

Where eQcell is headquartered

Location

Headquarters

HQ city
Guelph
HQ country
Canada
HQ region
North America

Offices1 record

Markets served

eQcell business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Veterinary Stem Cell Products: Once clinical trials complete and regulatory approvals achieved, eQcell will commercialize allogeneic MSC products for veterinary use in horses and dogs
  2. MSC Isolation Services: eQcell currently offers MSC isolation services for Canadian veterinarians for autologous use of cells in horses and dogs, and individual autologous cell banking of equine cord blood MSCs

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goResearch cell products and services

Go-to-market motion2 records

Distribution channels3 records

Marketing channels7 records

eQcell product offering

Product offering

Core offering

eQcell develops and supplies allogeneic mesenchymal stromal cell (MSC) products — equine cord blood-derived CB-MSCs and canine adipose-derived MSCs — for veterinary use, alongside MSC isolation services and autologous cell banking for Canadian veterinarians. The company is currently clinical-stage, advancing these biologics through veterinary clinical trials (with pivotal trials anticipated in 2026) toward regulatory approval via FDA INAD and Health Canada's Veterinary Drug Directorate.

Product overview

eQcell is a clinical-stage regenerative medicine company offering the eQcell Quality Cell Series™ product line, which includes banked allogeneic cells and autologous cell services. The core products consist of equine allogeneic cord blood stem cells (CB-MSCs) for treating osteoarthritis in horses and canine adipose-derived mesenchymal stromal cells for treating elbow dysplasia and osteoarthritis in dogs. The company also provides MSC isolation services and autologous cell banking for Canadian veterinarians. The company is pursuing veterinary drug approvals through clinical trials designed to generate data for pivotal trials anticipated to initiate in 2026.

Differentiator

Problem solved

Functional benefit

Brands

  • eQcell Quality Cell Series™: Banked allogeneic cells and autologous cell services for domestic animal cells including equine and canine applications.

Products and services

  • eQcell Quality Cell Series™ Branded product line comprising banked allogeneic cells and autologous cell services for domestic animal (equine and canine) applications, with custom cell procurement available on request.
  • Equine Allogeneic Cord Blood Stem Cells (CB-MSCs) Allogeneic equine cord blood mesenchymal stromal cells designed to provide veterinarians with off-the-shelf therapeutics for treating osteoarthritis and joint conditions in horses, replacing laborious autologous extraction-expansion-re-injection workflows.
  • Canine Adipose-Derived Mesenchymal Stromal Cells Canine adipose-derived mesenchymal stromal cells developed as an allogeneic treatment option for immune and inflammatory disorders in dogs, particularly elbow dysplasia and osteoarthritis.
  • MSC Isolation Services MSC isolation services provided to Canadian veterinarians for autologous use of cells in horses and dogs.
  • Equine Cord Blood MSC Autologous Cell Banking Individual autologous cell banking service for equine cord blood mesenchymal stromal cells, provided to Canadian veterinarians.

Quantifiable outcome

  • Horses treated with eQcell's stem cells are 3.4x more likely to return to previous work compared with hyaluronic acid
  • +2 more outcomes

Companies that use eQcell

Customer profile

Named customers6 records

Segments2 records

Ideal customer profiles2 records

eQcell technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

eQcell partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered supporting and core.

  • Likarda LLCsupportingTechnology or Integration · 17 February 2022Licensing option agreement for proprietary hydrogels for MSC encapsulation, announced February 17, 2022.
  • University of Guelph / Ontario Veterinary CollegecoreStrategic or Co-development PartnerFounding academic partner. eQcell was founded based on 15 years of scientific investigation at OVC, ranked 6th in the world for veterinary science. OVC researchers (Dr. Judith Koenig, Dr. Melissa MacIver) serve as lead investigators for clinical trials.
  • Colorado State UniversitycoreStrategic or Co-development PartnerDr. C. Wayne McIlwraith (Founding Director of Orthopaedic Research Center) serves on Board of Directors. Dr. Laurie Goodrich and Dr. Lynn Pezzanite serve on Scientific Advisory Board. CSU's Translational Medicine Institute is key research partner.
  • Moore Equine Veterinary ServicessupportingImplementation/ SI/ Consulting PartnerCollaborating equine veterinary clinic participating in clinical trials and research activities.
  • Rood and Riddle Equine HospitalsupportingImplementation/ SI/ Consulting PartnerCollaborating equine veterinary hospital in Kentucky participating in research partnership for septic arthritis treatment studies.
  • Equine PIsupportingTechnology or IntegrationTechnology partner providing equine performance and health analytics integration.
  • Dechra CanadasupportingStrategic or Co-development PartnerSponsor for synovitis clinical trial comparing MSC treatment to hyaluronic acid.

Scale indicators4 records

Recent moves1 record

Expansion highlights6 records

eQcell competitors and assessment

Company assessment

Direct peers

  • Regeneus: Regeneus is an Australian clinical-stage regenerative medicine company developing allogeneic stem cell therapies, including Progenza for osteoarthritis. It is comparable to eQcell in technology platform (allogeneic MSCs), indication focus (osteoarthritis), and clinical-stage status.
  • MediVet Biologics: MediVet Biologics develops and commercializes regenerative medicine therapies for horses and companion animals, including platelet-rich plasma and stem cell products. It overlaps directly with eQcell's target indications (equine and canine joint disease) and competes for the same veterinary clinic customers.
  • VetStem Biopharma: VetStem Biopharma is a U.S.-based veterinary regenerative medicine company offering autologous stem cell services for horses, dogs and cats. It is the most direct competitor to eQcell in equine and companion-animal stem cell therapy, although it relies on autologous rather than allogeneic cells.

Broad incumbents

  • Vetoquinol: Vetoquinol is a global animal health pharmaceutical company with strong equine and companion-animal presence. It is comparable as a broad incumbent that markets joint and orthopedic therapeutics directly competitive with eQcell's intended indications.
  • Dechra Pharmaceuticals: Dechra is a global specialty animal health pharmaceuticals company that is already an eQcell clinical trial sponsor (synovitis study comparing MSC therapy to hyaluronic acid). It is a broad incumbent with deep equine veterinary relationships and represents both a near-term partner and a potential strategic acquirer of eQcell's regenerative medicine platform.
  • Elanco Animal Health: Elanco is a major global animal health company with a broad companion-animal and livestock portfolio. It represents a broad incumbent that has been expanding into specialty and regenerative categories and could either compete with or acquire a clinical-stage MSC asset like eQcell.
  • Boehringer Ingelheim Animal Health: Boehringer Ingelheim Animal Health is one of the largest global animal health players, with significant equine and companion-animal pharmaceutical portfolios. It is comparable as a broad incumbent that could in-license or develop competing regenerative therapies and has the distribution muscle to dominate the equine OA market.
  • Virbac: Virbac is a global animal health company with equine and companion-animal pharmaceutical offerings, including orthopedic and pain management products that compete with the indications eQcell is targeting. As a broad incumbent it is both a potential competitor and a strategic partner candidate.
  • Zoetis: Zoetis is the world's largest animal health company with a broad portfolio of pharmaceuticals, vaccines, diagnostics and increasingly regenerative medicine. It competes indirectly through its scale, sales force, and capital capacity and is a potential strategic partner or acquirer for eQcell's MSC platform.

Emerging players

  • EquiCord: EquiCord provides equine umbilical cord blood banking services. It is comparable to eQcell because it sits on the same equine cord blood sourcing infrastructure that underpins eQcell's allogeneic CB-MSC product, and it represents both a potential supplier and a competing entry point for equine regenerative medicine.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights8 records

Customer concentration

eQcell social profiles

Digital presence

eQcell financial estimates

Financial estimate

Revenue estimate

Valuation estimate

eQcell leadership team

Management profile

Number of profiles

Profiles8 records

eQcell funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

eQcell M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about eQcell

What does eQcell do?

eQcell develops and supplies allogeneic mesenchymal stromal cell (MSC) products — equine cord blood-derived CB-MSCs and canine adipose-derived MSCs — for veterinary use, alongside MSC isolation services and autologous cell banking for Canadian veterinarians. The company is currently clinical-stage, advancing these biologics through veterinary clinical trials (with pivotal trials anticipated in 2026) toward regulatory approval via FDA INAD and Health Canada's Veterinary Drug Directorate.

Is eQcell a public or private company?

eQcell is a private company. It is classified as venture growth investor backed and is currently operating.

When was eQcell founded?

eQcell was founded in 2010. It employs 11 to 50 people.

Where is eQcell based?

eQcell is headquartered in Guelph, Canada, in the North America region.

How does eQcell make money?

Two revenue lines are on record. Veterinary Stem Cell Products are the primary driver. The others are MSC Isolation Services.

Who are eQcell's main competitors?

Direct peers on record are Regeneus, MediVet Biologics and VetStem Biopharma. Broad incumbents are Vetoquinol, Dechra Pharmaceuticals, Elanco Animal Health, Boehringer Ingelheim Animal Health, Virbac and Zoetis. EquiCord is listed as an emerging player.

Does eQcell have an API?

No public API is recorded for eQcell.

What industry is eQcell in?

eQcell's product category is Veterinary Regenerative Medicine. Its primary akta.pro industry code is HLAMANAI, Veterinary Regenerative Medicine Manufacturing (GMP/CDMO, Cell Processing), with a secondary code of HLAMANAL, Clinical Research, Trials & Translational Services (Veterinary Regenerative). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales